Skip to main content

Table 1 Estimates of prevalence of newly diagnosed diabetes, known diabetes and IFG among Iranian adults 25–64 years old

From: Third national surveillance of risk factors of non-communicable diseases (SuRFNCD-2007) in Iran: methods and results on prevalence of diabetes, hypertension, obesity, central obesity, and dyslipidemia

  Impaired Fasting Glucoseab Known DM New DMa New and Known DMa
  National estimatec Prevalence
(95% CI)
National estimatec Prevalence
(95% CI)
National estimatec Prevalence
(95% CI)
National estimatec Prevalence
(95% CI)
Age         
   25–34 (n = 843) 0.6 5.1 (3.4–7.6) 0.1 0.7 (0.3–1.5) 0.3 2.5 (1.4–4.4) 0.4 3.2 (2.0–5.0)
   35–44 (n = 902) 0.9 10.0 (7.6–13.0) 0.4 4.9 (3.3–7.3) 0.4 4.3 (3.2–5.8) 0.8 9.2 (7.0–12.1)
   45–54 (n = 869) 0.9 13.6 (11.5–16.1) 0.5 8.4 (6.7–10.4) 0.4 5.6 (3.5–8.7) 0.9 14.0 (11.2–17.3)
   55–64 (n = 783) 0.5 14.6 (11.9–17.9) 0.4 12.1 (8.2–17.4) 0.2 6.7 (4.9–9.1) 0.6 18.8 (14.7–23.6)
Sex         
   Males (n = 1645) 1.5 9.3 (7.7–11.3) 0.7 4.4 (3.1–6.1) 0.6 4.0 (3.1–5.2) 1.3 8.4 (6.6–10.5)
   Females (n = 1752) 1.4 9.0 (7.2–11.3) 0.8 4.9 (3.8–6.2) 0.7 4.2 (2.9–6.0) 1.4 9.1 (7.4–11.2)
Residential area         
   Urban (n = 2175) 2.1 9.8 (8.3–11.4) 1.1 4.9 (3.9–6.2) 1.0 4.3 (3.4–5.4) 2.1 9.2 (7.8–10.9)
   Rural (n = 1222) 0.7 7.8 (5.4–11.1) 0.3 3.9 (2.4–6.1) 0.3 3.7 (2.1–6.3) 0.7 7.5 (5.2–10.9)
Total national estimate
(n = 3397)
2.9 9.2 (7.9–10.7) 1.5 4.6 (3.8–5.7) 1.3 4.1 (3.3–5.1) 2.7 8.7 (7.4–10.2)
  1. DM: Diabetes mellitus, CI: confidence interval
  2. a In subjects with valid fasting plasma glucose measurements
  3. b In non-diabetic subjects
  4. c Rounded to the nearest million
  5. Estimates are weighted for age, sex, and residential area on the basis of the population of Iran in 2006